(Al-Quds University - Deanship of Scientific Research, 2023-05-16) Amneh Hawamdeh; Rasha Alnatsheh; Lina Alhasani; Haneen Nur; Abeer Ghanayem
Background: Renal Anemia is a prevalent condition among end-stage of chronic kidney disease (CKD), especially among patients undergoing hemodialysis (HD) due to erythropoietin deficiency. Uncontrolled anemia treatment is a major contributing factor for increased mortality and significant decrease in the Quality of Life (QoL). Medical protocols of renal anemia for end stage CKD patients vary between blood transfusion, erythropoiesis stimulating agents (ESAs) therapy
or iron supplements. Palestinian hemodialysis patients receive medical care and treatment in the governmental hospitals. However, the clinical outcomes for HD patients are not clearly assessed.